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Objectives: To identify a stable biochemical marker of disease severity in patients with intermittent claudication and to 
use these findings to assess the effect of therapeutic exercise training. 
Design: Case-control study: prospective randomised-controlled trial of exercise training. 
Materials and methods: Plasma fibrinogen, serum amyloid A protein (SAA), C-reactive protein (CRP) and urinary 
albumin-creatinine ratio (ACR) were measured in 67 claudicants and 15 controls. Twenty-two patients were randomised 
to supervised exercise training and 17 randomised to observation. Subjects were reviewed at 3, 6 and 12 months. 
Results: The median (interquartile range) baseline fibrinogen was 3.7 gfl (3.3-4.25) in claudicants and 3.5g/I (2.9-3.95) 
in controls (p=0.045); CRP was 4.7 mg/I (2.2-9.0) and 2.1 mg/I (1.0-2.8), respectively (p<O.O001); SAA was 72 mg/I 
(35-132) and 30 mg/l (20-89) (p = 0.0009). Claudicants howed an increased urinary ACR following treadmill exercise 
(Wilcoxon, p<O.O001) with no change in controls. Exercise training reduced SAA at 6 months, CRP at 3 months and 
progressively attenuated the post-exercise increase in ACR. No similar changes were found in controls. 
Conclusions: Repetitive low-grade inflammatory events in claudicants lead to elevation of serum acute-phase proteins. 
Exercise training is associated with symptomatic improvement and reduction in inflammatory markers. The concern that 
exercise has adverse systemic effects therefore seems to be unjustified. 
Key Words: Intermittent claudication; Exercise; Serum amyloid A protein; C-reactive protein; Fibrinogen. 
Introduction 
Recent work has suggested that in patients with in- 
termittent claudication, repeated episodes of calf or 
buttock pain followed by rest may be considered as 
low-grade ischaemia-reperfusion njuries. The result 
of this is oxygen-derived free radical formation, 1 
neutrophil activation 2 and systemic vascular endo- 
thelial damage, 3 i.e. local skeletal muscle ischaemia 
leads to a systemic inflammatory response. It is still 
unclear as to whether these repeated low-grade in- 
f lammatory events have any clinical significance, al- 
though it is tempting to postulate that they are 
implicated in the progression of atherosclerosis. This 
may explain the excess cardiovascular mortality - at 
least 50% at 10 years - seen in these patients. 4 
In routine clinical practice, measurement of these 
transient acute inflammatory markers is impractical, 
as pre- and post-exercise testing, immediate sample 
processing and specialist laboratory facilities are often 
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required. The primary aim of this study was therefore 
to identify a stable biochemical marker which could 
be used as a measure of disease severity. Previous 
work has shown that macrophages are intrinsically 
involved in  complex atherosclerotic plaque. 5 Macro- 
phages are the main source of pro-inflammatory c to- 
kines which induce hepatic acute-phase protein 
synthesis. This study was therefore designed to assess 
the potential use of the acute-phase proteins C-reactive 
(CRP) and serum amyloid A protein (SAA) as markers 
of vascular inflammation. 
The secondary aim of the study was to use these 
inflammatory markers to assess the treatment of in- 
termittent claudication. The beneficial effects of ex- 
ercise training as a treatment have been confirmed in 
several randomised controlled trials. A recent meta- 
analysis of 33 trials showed 179% improvement in 
pain-free walking distance and 122% improvement in
maximum walking distance following exercise train- 
ing. 6 The adverse effects of encouraging exercise to 
the limit of ischaemic pain have, however, not been 
explored. This study aimed to determine the effect 
of these "forced" ischaemic events on biochemical 
markers of inflammation. 
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Materials and Methods 
Sixty-seven stable claudicants were recruited from a 
claudicant register kept at the Royal South Hampshire 
Hospital. The screening inclusion criteria were ex- 
ercise-limiting calf pain on walking of at least 6 
months' duration, a positive Edinburgh Claudication 
Questionnaire, 7 a Doppler ankle-brachial pressure 
index (ABPI) <0.8 and at least 30 mmHg drop in ankle 
systolic pressure following a i min treadmill test. Pain- 
free (PFWD) and maximum walking distances (MWD) 
were measured by constant-load treadmill testing 
(3 km/h  on a 10% gradient), and patients were re- 
cruited if the walking distance was between 50 and 
250 m. Exclusion criteria were a significant improve- 
ment or deterioration in claudication symptoms within 
the previous 6 months, therapeutic intervention for 
peripheral vascular disease within the previous 6 
months, exercise limited by symptoms other than clau- 
dication, any concurrent inflammatory disease such 
as rheumatoid arthritis or inflammatory bowel disease, 
treatment with steroids or an inability to complete 
the assessment visits or comply with the allocated 
treatment. All 67 claudicants were given a standard 
leaflet advising on weight loss, smoking and exercise, 
and were prescribed aspirin 75 mg daily unless con- 
traindicated. Fifteen control subjects were also re- 
cruited, either from normal volunteers or at least 5 
months following elective minor or intermediate non- 
arterial elective general surgery. Controls were re- 
cruited if there were no symptoms of calf pain on 
walking, if the ABPI was >1.0 and there was no fall 
in ankle pressure following a i min treadmill test. 
Following screening, subjects attended for the first 
assessment 2 weeks later. Subjects were asked not to 
exercise prior to the visit and were transported to the 
vascular laboratory by wheelchair, to avoid initiating 
claudication pain. Subjects emptied their bladders im- 
mediately on arrival and after 30 min rest a further 
urine sample was obtained for baseline urinary micro- 
albumin excretion. Resting blood samples were also 
taken for fibrinogen, CRP and SAA. The resting ABPI 
was determined and then subjects performed constant- 
load treadmill testing to determine the PFWD and 
MWD. The fall in Doppler ankle pressure following 
exercise was noted. A further urine sample was taken 
60 min following exercise to measure the change in 
albumin excretion. Our previous work has confirmed 
that an increase in renovascular permeability to al- 
bumin reflects systemic vascular endothelial injury, s
Patients were re-assessed after 4 weeks to determine 
the variability of the measurements. 
Plasma fibrinogen was measured on an ACL 1000 
automated analyser, which derives a fibrinogen level 
from the rate of clot formation and has a within-batch 
coefficient of variation of 3-5% at 1.4-5 g/1. CRP was 
measured by an "in-house" enzyme-linked immuno- 
sorbent assay (ELISA) with a limit of detection of 
0.1 mg/1, a reported reference range of <2.4 rag/1 and 
a coefficient of variation of 9.6% at 0.1-32 mg/1. SAA 
was measured using a commercial][y available ELISA 
kit (Biosource, Camarillo, California, U.S.A.) with a 
limit of detection of 5 rag/1. Serum samples required 
a 1:1000 dilution to detect SAA, and the coefficient of 
variation between duplicates ranged from 9.5% to 
16.2%. Urinary microalbumin excretion was expressed 
as the albumin-creatinine ratio (ACR) to correct for 
variation in urinary flow-rate. Urinary albumin was 
measured by radio-immunoassay (Diagnostic Prod- 
ucts Corporation, Caernavon, U.K.) and urinary cre- 
atinine was measured by an automated Jaffe reaction 
using an ILAB 900 analyser (Instrumental Laboratories 
Ltd, Warrington, U.K.). 
Following the second assessment subjects were ran- 
domised to either observation (n = 17), a supervised 
exercise training programme (n = 22) or percutaneous 
transluminal ngioplasty (n= 28). Further work is con- 
tinuing in the angioplasty arm of the trial, and therefore 
these results are not reported in this paper. The exercise 
group attended group classes weekly for 4 weeks, 
lasting for I h. The programme consisted of a series 
of active and passive leg exercises performed to the 
limit of claudication pain. The sessions were su- 
pervised by a single physiotherapist (MH) and were 
designed to teach the exercises and tailor them to 
the individual patient. Patients were encouraged to 
exercise for at least 45 min every day at home, in 
addition to daily walks of at least 1 mile. All patients 
were then followed up at 3, 6 and 12 months using 
the same protocol. 
The biochemical data were non-parametrically dis- 
tributed and were expressed as the median (in- 
terquartile range (IQR)) and analysed using the 
Wilcoxon signed rank test within subjects and the 
Mann-Whitney U-test between subjects. Spearman 
correlation coefficients were derived from the 
weighted mean of the two measurements. 9 The ABPI 
was normally distributed and data were therefore 
analysed using paired and unpaired t-tests. SPSS 
PC+v4.0 was used for the statistical analysis. 
Results 
The demographic data for patients and controls are 
shown in Table 1. Thirty-nine claudicants were cur- 
rently taking low-dose aspirin for anti-platelet pro- 
phylaxis. Eleven claudicants (16.4%) had undergone 
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Table 1. Demographic data of claudicants and control subjects. 
Claudicants Controls 
Sex Male 
Female 
Age Mean 
IHD 
CVD 
Hypertension 
Diabetes 
Hyperlipidaemia 
Smoking 
Current angina 
Previous myocardial infarction 
Coronary artery bypass urgery 
Transient ischaemic attack 
Stroke 
Carotid endarterectomy 
BP >150/90: no treatment 
BP >150/90: with treatment 
BP <150/90: with treatment 
Current 
Ex 
Non 
46 (68.7%) 9 (60%) 
21 (31.3%) 6 (40%) 
69.3 66.2 
25 (37.3%) 1 (6.7%) 
13 1 
11 
8 
8 (11.9%) 0% 
6 
2 
3 
51 (76.1%) 9 (60%) 
30 9 
21 
4 
7 (10.4%) 0% 
6 (9.0%) 0% 
20 (29.9%) 2 (13.3%) 
41 (61.1%) 1 (6.7%) 
6 (9.0%) 12 (80%) 
previous interventions for peripheral arterial disease. 
Three patients had a previous aortobifemoral graft and 
six had a previous common iliac artery angioplasty, of 
which four were contralateral nd two ipsilateral to 
the symptomatic leg. 
The median (IQR) resting ACR in the claudicants at 
baseline was 1.24 mg/mmol  (0.71-3.65) compared to 
1 .04mg/mmol  (0.55-1.77) in control subjects. There 
was no statistical difference between the two groups 
(Main't-Whitney U-test, p=0.14). The claudicants, 
however, showed a statistically significant increase 
in ACR following treadmill exercise (Wilcoxon, p = 
0.0001) while the controls showed an insignificant 
decrease (p = 0.48") (Fig. 1). 
The claudicant group had significantly higher 
c~ 
Claudicant 
5 -  
4 -  
2 
1 
I 
Rest Exercise 
Control 
Rest Exercise 
Fig. 1. Urinary albumin-creatine ratio (ACR) pre- and post-exercise 
in claudicants and control subjects at baseline. Results are shown 
as the median + interquartile range. 
levels of fibrinogen (Mann-Whitney, p=0.045) CRP 
(p<0.0001) and SAA (p = 0.0009) than control subjects 
(Table 2). Comparison of data from the two baseline 
visits within the claudicant group showed no stat- 
istically significant difference between parameters, 
with the exception of PFWD, which increased on the 
second visit (Wilcoxon, p =0.0006). This is probably 
due to the familiarity with treadmill walking, high- 
lighting the inaccuracy of this method of assessing 
severity of claudication. 
Using the weighted mean of the claudicant data, 
significant correlations were found between baseline 
SAA and CRP (r=0.56, p<0.0001) (Fig. 2), fibrinogen 
(r =0.43, p<0.001) and PFWD (r= -0.27, p =0.03) with 
borderline significant correlation with MWD (r= 
- 0.23, p = 0.06). 
Analysis of treatment subgroups showed no dif- 
ference between baseline parameters in those patients 
randomised to exercise or observation. All patients in 
the exercise group attended all four physiotherapy 
training sessions, apart from one patient who missed 
two sessions due to an exercise-induced Achilles 
tendon strain. Good compliance with the exercise 
Table 2. Baseline acute-phase protein levels in claudicants and 
control subjects. Results are shown as the median (interquartile 
range). 
Claudicants (n= 67) Controls (n= 15) 
Fibrinogen (g/l) 3.7 (3.3-4.25) 3.5 (2.9-3.95) 
CRP (mg/1) 4.7 (2.2-9.0) 2.1 (1.0-2.8) 
SAA(mg/I) 72 (35-132) 30 (20-89) 
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Table 3. Change in clinical and biochemical parameters in patients undergoing exercise training (EX) and observation (OBS). Results 
are shown as the median (interquartile range), except for ABPI which is shown as the mean (standard error of mean). Statistics are 
shown for change with time in comparison to baseline (* p<0.05, ~ p<0.01, :~ p<0.001) and across time between exercise and observation 
groups (§p<0.05 for exercise>observation). 
Parameter Rx Baseline 3 months 6 months 12 months 
Fibrinogen (g/l) EX 3.7 (3.4-4.0) (n=22) 3.8 (3.6-4.3) (n=21) 3.8 (3.2-4.4) (n=17) 3.9 (3.4-4.6) (n=10) 
OB 4.0 (3.7-4.6) (n=17) 4.2 (3.3-4.6) (n=13) 4.4 (3.8-4.6) (n=12) 4.0 (3.5-4.8) (n=9) 
CRP (rag/l) EX 5.3 (2.8-10.5) 4.4 (1.8-7.2)* 6.6 (3.4-9.0) 4.8 (2.2-9.3) 
OB 5.6 (2.7-8.9) 4.8 (2.1-9.2) 5.4 (1.8-12.6) 2.0 (0.8-15.0) 
SAA (rag/l) EX 70 (54-118) 52 (31-84) 20 (5-64)t 23 (16-102) 
OX 94 (39-167) 106 (32-285) 68 (38-104) 44 (24-206) 
ABPI EX 0.66 (0.02) 0.64 (0.03) 0.65 (0.03) 0.64 (0.05) 
OB 0.70 (0.03) 0.69 (0.03) 0.72 (0.05) 0.74 (0.07) 
PFWD (m) EX 70 (45-87) 106 (72-145):~ 94 (82-273)$ 112 (103-258)t 
OB 80 (44-91) 75 (60-89)§ 77 (56-93) 107 (67-137)? 
MWD (m) EX 104 (72-148) 182 (116-238)$ 166 (94-313)t 175 (103-258)t 
OB 110 (81-148) 109 (81-135)§ 93 (82-148)§ 126 (104-156)t 
PFWD = pain-free walking distance; MWD = maximum walking distance. 
p rogramme was achieved at all fol low-up times. The 
mean number  of weekly exercise sessions elf-reported 
was 6.3 at 3 months, 5.6 at 6 months and 4.9 at 12 
months. 
At baseline there was no significant difference be- 
tween the two groups in both PFWD and MWD. At 
3 months, the PFWD and MWD were significantly 
higher in the exercise group compared to the control 
group (Mann-Whitney, p= 0.047, 0.029) and this was 
maintained in MWD at 6 month fol low-up (p = 0.028). 
At 12 months the differences were of borderl ine sig- 
nificance, possibly due to smaller numbers reaching 
this time-point. 
The change in parameters within the exercise group 
are shown in Table 3. A significant decrease in CRP 
was found at 3 months '  fol low-up and a significant 
2500 
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Fig. 2. Correlation of serum amyloid A protein and C-reactive 
protein in daudicants. (Spearman r=0.56, p = <0.0001). 
decrease in SAA was shown at 6 months, with a 
borderl ine significant decrease at 12 months (Wilcoxon, 
p = 0.07). Within the exercise group, the post-exercise 
increase in the urinary ACR was significant at baseline 
(p=0.025). At 3 months'  fol low-up there was at- 
tenuation of the post-exercise increase (p = 0.10) with 
further decreases at 6 and 12 months (p=0.136, p= 
0.138). No similar change in inf lammatory markers 
were seen in the control group. 'l-he controls also 
showed improvement  in both PFWD and MWD at 12 
months (both p =0.008). 
Discussion 
The results clearly support the idea that exercise in 
patients with intermittent claudication leads to an 
inf lammatory response. In agreement with previous 
work, claudicants and controls howed no difference in 
baseline urinary albumin excretion, while claudicants 
alone had a significant increase following treadmill 
exercise to the onset of calf pain, reflecting increased 
vascular endothelial permeabi l i tyY ° 
The elevated acute-phase protein levels in clau- 
dicants are also consistent with the concept of re- 
petitive low-grade ischaemia-reperfusion injury (calf 
pain followed by rest) leading to a cumulative in- 
f lammatory response. If untreated, one would expect 
that this would have important implications for the 
progression of atherosclerosis and subsequent cardio- 
vascular morbidity and mortality. Fibrinogen is well 
established as an important risk factor for the onset 
of intermittent claudication, 11as well for progression of 
peripheral arterial disease (PAD) ~2 and cardiovascular 
death. 13 However,  the prognostic significance of an 
isolated fibrinogen measurement is uninterpretable, 
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due to the influence of numerous variables such as 
age, sex, obesity, smoking, alcohol intake, diabetes, 
genetic variability and assay method. ~4"15 
C-reactive protein and serum amyloid A protein are 
both detectable 6-8 h following an inflammatory event, 
reaching amaximum 20-30 h later. Serum levels there- 
fore reflect the cumulative effect of repeated in- 
flammatory events. Within the claudicant group, SAA 
and CRP concentrations were significantly correlated. 
Since difference macrophage-derived cytokines induce 
synthesis of each protein, predominantly interleukin- 
6 for CRP and interleukin-1 for SAA, this suggests 
that the inflammatory response in claudicants may be 
a consequence of activation of macrophages within 
atherosclerotic plaque. 5SAA and CRP are not strongly 
influenced by variables of vascular inflammation, as- 
suming no other co-existent inflammatory pathology 
is present. There has been very little published work 
on the use of CRP as a marker of peripheral arterial 
disease (PAD). Majewski et al. ~6 measured CRP in 107 
patients with PAD and found an association with the 
severity of ischaemia. However, in the 20 claudicants 
the median CRP was only i mg/1, perhaps reflecting 
the insensitivity of the assay used. The median CRP 
in our study was 4.7 rag/l, which is within the normal 
range of many assays. Since Pepys ~7 reports that the 
median CRP in healthy individuals hould be 0.8 mg/ 
1, we suggest that small increases within this "normal" 
range may represent significant inflammatory events. 
We are not aware of any clinical studies reporting 
the measurement of SAA in peripheral arterial disease, 
although SAA has been studied in the assessment 
of myocardial infarction and unstable angina. 18 The 
predominant site of SAA synthesis is in hepatocytes, 
although SAA messenger RNA has also been docu- 
mented in vascular endothelial cells, macrophages and 
smooth muscle cells, suggesting that local synthesis 
in atherosclerotic plaque may also be important. 19 The 
main effect of SAA appears to be protective. SAA is 
synthesised as a result of macrophage activation within 
plaque. Macrophage activation is associated with ox- 
idation of low-density lipoprotein, which undoubtedly 
has a significant causative role in atherogenesis. SAA 
binds to high-density lipoprotein (HDL), increasing 
the affinity of HDL for subendothelial macrophages, 2° 
and thus making HDL available to mop up oxidised 
lipid debris and transport it to the liver. 
Exercise training programmes have been widely 
reported in the literature, although ave not yet gained 
widespread use in this country. Exercise is applicable 
to all claudicants and the potential benefit is unaffected 
by age, sex, diabetes and the anatomical location of 
the atherosclerotic plaqueY Exercise training is also 
cost-effective in comparison to other treatment options. 
Recent work has suggested that for a 10% improve- 
ment in PFWD at 6 months, exercise supervised for 
2 h twice weekly costs $115 in comparison to $3637 
for percutaneous transluminal angioplasty. 22Several 
randomised-controlled trials have confirmed that ex- 
ercise training leads to a significantly greater increase 
in PFWD and MWD than in control subjects. 23-25 Ex- 
ercise also compares favourably with other treatment 
options. An important randomised trial of exercise 
versus angioplasty showed that in the short-term, 
exercise led to a progressive increase in PFWD and 
MWD up to 15 months, while the angioplasty group 
had an insignificant initial increase followed by a 
deterioration. 26 Long-term follow-up of this cohort of 
patients, however, showed that the MWD in the ex- 
ercise group had deteriorated at 6 years' follow-up, 
although only limited numbers of patients reached 
this time-point. 27 Exercise training also appears to 
confer significant additional benefit on patients fol- 
lowing surgical reconstruction5 s 
To achieve these treatment effects exercise is best 
supervised, at least initially, by a physiotherapist, 29 
and the training should last for at least 6 months. 6 
However, as one is encouraging patients to exercise 
to the limit of ischaemic alf pain, 3° there is obviously 
concern that vascular inflammation may be po- 
tentiated, leading to adverse cardiovascular effects. 
We are not aware of any other studies reporting the 
effects of exercise training on these inflammatory 
markers. 
The results show that exercise training leads to a 
significant increase in pain-free and maximum walking 
distances by 3 months, which persisted at 12 months' 
follow-up. The results also clearly show that exercise 
training leads to a significant reduction or "nor- 
malisation" in SAA at 6 and 12 months' follow-up. 
CRP levels decreased at 3 months' follow-up, although 
this became insignificant at later follow-up. In the 
exercise group there was a progressive attenuation of 
the post-exercise increase in ACR, such that there 
was no significant difference between pre- and post- 
exercise measurements by 3 months' follow-up. These 
urinary albumin changes are similar to those found 
by Hickey et al. 31 following surgical bypass for clau- 
dication. 
This study suggests that exercise is indeed beneficial, 
both in terms of symptomatic improvement and re- 
duction of inflammatory markers. The mechanism of 
the improvement is unclear, but may perhaps be due to 
metabolic adaptation of skeletal muscle with improved 
oxygen utilisation. Lundgren et al. 2s showed an increase 
in cytochrome oxidase in gastrocnemius muscle biop- 
sies taken after 6 to 12 months of exercise training, 
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which correlated with the increase in walking distance. 
We suggest that the destructive potential of each isch- 
aemia-reperfusion event, calf pain followed by rest, 
may therefore be reduced. 
The findings of this study have an important bearing 
on overall health, as exercise undoubtedly reduces the 
incidence of ischaemic heart disease, s2 It therefore 
appears afe to advise patients to continue to exercise 
to the limit of claudication pain. 
Conclusion 
Patients with intermittent claudication appear to un- 
dergo repeated low-grade inflammatory episodes lead- 
ing to elevation of the acute-phase proteins C-reactive 
protein and serum amyloid A protein. These markers 
appear to reflect disease severity, as they correlate 
with known risk factors for cardiovascular disease 
(fibrinogen) and symptoms (treadmill walking dis- 
tances). Exercise training programmes supervised by 
a physiotherapist lead to a significant improvement 
in pain-free and maximum walking distances. In view 
of current theories of exercise-induced inflammation 
in claudication, one might expect long-term exercise 
to lead to a greater inflammatory response. This paper 
suggests that exercise training does not lead to an 
increase in biochemical markers of inflammation. On 
the contrary, exercise leads to a reduction in the level 
of serum amyloid A protein and attenuation of the 
post-exercise increase in urinary albumin excretion. 
By extrapolation, we suggest that exercise training 
may be beneficial in terms of future cardiovascular 
morbidity and mortality in patients with intermittent 
claudication. 
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